GLP-1 medications can create opportunity for change—but environment determines what lasts. Discover how context shapes habits ...

MEDVi, a telehealth platform serving more than 100,000 patients, today announced an expanded physician-led program ...

Up until recently, all three GLP-1 drugs for weight loss were only available in injectable form. However, the FDA approved the oral version of Wegovy® on December 22, 2025. The oral tablet, also known ...

For years, the pancreas has been being taught in biology class as an easy system: insulin lowers blood sugar, and glucagon raises it. But that’s much too simple, new research says. Scientists at Duke ...

Diabetes care is undergoing a major transformation driven by GLP-1 receptor agonists, which have expanded beyond glycemic ...

New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about ...

GLP-1 receptor agonists were linked to a small long-term reduction in vertebral fractures in a cohort study. The retrospective study was based on electronic health records of people with type 2 ...

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease in the Western world, driven by obesity, insulin resistance, and systemic inflammation.

LMNT reports that GLP-1 medications for obesity and diabetes may lead to electrolyte imbalances, highlighting hydration ...

Researchers are exploring drugs like Ozempic, Mounjaro, and Wegovy to treat or prevent a range of conditions, including cancer and arthritis.